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Abstract: Advances in understanding disease pathogenesis correlates to modifications in gene
expression within different tissues and organ systems. In depth knowledge about the dysregulation
of gene expression profiles is fundamental to fully uncover mechanisms in disease development
and changes in host homeostasis. The body of knowledge surrounding mammalian regulatory
elements, specifically regulators of chromatin structure, transcriptional and translational activation,
has considerably surged within the past decade. A set of key regulators whose function still needs to
be fully elucidated are small non-coding RNAs (sncRNAs). Due to their broad range of unfolding
functions in the regulation of gene expression during transcription and translation, sncRNAs are
becoming vital to many cellular processes. Within the past decade, a novel class of sncRNAs called
PIWI-interacting RNAs (piRNAs) have been implicated in various diseases, and understanding their
complete function is of vital importance. Historically, piRNAs have been shown to be indispensable
in germline integrity and stem cell development. Accumulating research evidence continue to reveal
the many arms of piRNA function. Although piRNA function and biogenesis has been extensively
studied in Drosophila, it is thought that they play similar roles in vertebrate species, including humans.
Compounding evidence suggests that piRNAs encompass a wider functional range than small
interfering RNAs (siRNAs) and microRNAs (miRNAs), which have been studied more in terms of
cellular homeostasis and disease. This review aims to summarize contemporary knowledge regarding
biogenesis, and homeostatic function of piRNAs and their emerging roles in the development of
pathologies related to cardiomyopathies, cancer, and infectious diseases.
Keywords: piRNAs; piRNA function; piRNAs in disease pathogenesis; sncRNA
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1. Introduction
Understanding the interplay between noncoding and coding RNAs represents a fastemerging field in biomedical research. Noncoding RNAs are classified as either long
non-coding RNAs (lncRNAs), which are usually longer than 200 nucleotides (nt) and
small non-coding RNAs (sncRNAs) that are anywhere between 18–35 nt in length. The
sncRNA that are currently known are classified into three main groups: small interfering
RNAs (siRNAs, about 21 nt), microRNAs (miRNAs, about 22 nt), and Piwi-interacting
RNAs (piRNAs, 24–32 nt in length) [1–3]. Although siRNAs and miRNAs have been
studied more extensively, piRNA biogenesis and function has not been investigated in
many species [4–12]. However, most of the knowledge about piRNA the biogenesis and
function come from studies in Drosophila. Currently, piRNAs are thought to be the most
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abundant sncRNA within the genome, with over 30,000 members, excluding growing numbers of piRNA isoforms recently discovered across other species [13,14]. Characterization
of piRNAs is dependent upon the binding with PIWI subfamily of Argonaute AGO/PIWI
proteins. Argonaute family proteins are RNA binding proteins containing the highly
conserved Piwi-Argonaute-Zwille domain (PAZ), the C-terminal PIWI domains, the less
conserved N-terminal (N) and Middle (Mid) domains [15]. The PAZ domain functions as
an RNA binding motif, and the PIWI domain retains RNase H fold domain, homologous to
RNase H, an endonuclease [16]. Thus, Argonaute proteins are divided into two categories:
AGO subfamily and PIWI subfamily. The PIWI subfamily proteins have been shown to be
expressed within the germline and adult stem cells, while the AGO subfamily of proteins
is ubiquitously expressed in most tissues. However, the literature shows that PIWI subfamily of proteins are also expressed in somatic cells, suggesting that piRNAs may exhibit
roles outside of germline integrity maintenance [17,18]. PIWI family proteins have also
been identified in mice and humans as MIWI and HIWI subfamilies, respectively [19,20].
The piRNA/Piwi complex interacts with various proteins that facilitate many functions,
including: piRNA biogenesis, transposon silencing, chromatin remodeling, transcriptional
and translational regulation [21]. Within the past decade, increasing number of reports
implicate piRNAs as modulators of various diseases including cardiomyopathies, cancer,
and infectious diseases (Table 1).
Table 1. piRNAs associated with various diseases.
Disease/
Pathology

piRNA

Upregulated/
Downregulated

Gene Target

Reference

Cardiac Hypertrophy/
Cardiac Failure

piR-141981/cardiachypertrophyassociated piRNA
(CHAPIR)

Upregulated in mice that
underwent transverse aortic
construction surgery

Myh7, Anp, Bnp, and
PARP10 mRNA

[22]

Cardiac Hypertrophy/
Cardiac Failure

piR-13375 and
piR-106654

Downregulated in mice that
underwent transverse aortic
construction surgery

Not identified

[22]

Cardiac Failure

has-piR-006426 and
has-piR-0200009

Downregulated in the serum
exosomes of patients experiencing
heart failure

Not identified

[23]

Myocardial Infarction

piR_2106027

Upregulated in the serum of
patients with Troponin-I negative
myocardial infarction

Troponin-I

[24]

Cardiac Tissue
Regeneration/
Angiogenesis

piR-55490

Not specified

mTOR

[25,26]

Breast Cancer

piR-4987

Upregulation promotes lymph
node metastasis

Not identified

[27]

[28]

Breast Cancer

piR-021285

Not specified

Induces
methylation
several genes
related to breast cancer
in vitro

Lung Cancer

piR-L-163

Upregulated upon cisplatin
treatment in vitro and in vivo

Regulates
ezrin-radixin-moesin
(ERM) proteins

[29]

Lung Cancer

piR-651

Upregulated

Promotes the
upregulation of cyclins
and CDKs

[30]
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Table 1. Cont.
Upregulated/
Downregulated

Gene Target

Reference

piR-1245

Upregulation promotes colorectal
cancer tumor growth

Suppresses multiple
tumor
suppressors such as
ATF3, DUSP1, and
SESN2

[31]

PiRNA-823

Upregulated in patients with
multiple myeloma

Regulates de novo
DNA methylases
DNMT3A and 3B and
angiogenesis

[32]

Bladder Cancer

piRNA-DQ594040

Upregulated in tissue from
patients with bladder cancer

May regulate
Tumor Necrosis Factor
Superfamily Member 4
(TNFSF4)

[33]

Liver Cancer

piR-Hep1

Upregulated in hepatocellular
carcinoma samples

Upregulates PI3K/AKT

[34,35]

Pancreatic
Cancer

piR-017061

Downregulated in pancreatic
ductal adenocarcinoma tissue

Not identified

[36]

Pancreatic
Cancer

piR-016658 and
piR-001311

Have been detected in the
extracellular RNA of pancreatic
cancer patients

Not identified

[36]

Trypanosoma cruzi
infection in cardiac
myocytes

piR-753 and piR-18573

Upregulate d during early phase
of infection

FOS

[37]

Disease/
Pathology

Colorectal
Cancer

Gastric Cancer

piRNA

2. Structure and Function of piRNAs
2.1. piRNA Structure and Biogenesis
P-element induced wimpy testis interacting RNAs (piRNAs) are the most recently
characterized class of small noncoding RNAs (sncRNAs). These RNA molecules are
found in germline and somatic cells. Their sizes range anywhere from 24–31 nucleotides
long and many reports identify a 50 terminal uridine or tenth adenosine [38]. These
sncRNAs have a unique feature in which a 20 O-methyl group on the 30 ribose is required
for maturation [39,40]. This 20 O-methyl group addition is performed by the piRNA
methyltransferase Hen1 (HENMT1), a step that is conserved in all organisms [40]. Loss of
Henmt1 caused piRNA instability via decreased piRNA abundance and size, as illustrated
by Lim et al. [41]. Mature piRNAs interact with a specific subset of argonaute proteins
called p-element induced wimpy testis (PIWI) proteins; these RNA binding proteins
interact with piRNAs, forming a ribonucleoprotein complex known as the piRNA induced
silencing complex (piRISC). The piRISC is guided by piRNAs to recognize sequences at
the chromatin, transcriptional, and post-transcriptional levels. Proteins containing Tudor
domains (TDRDs) also associate with PIWI proteins and have been shown to play an active
role in the piRNA metabolic pathway. TDRDs expedite piRISC action as well as bolster the
stability of PIWI proteins by acting as a molecular scaffold [42].
Biogenesis of sncRNA generally occurs in a Dicer/Drosha dependent manner, in which
double-stranded RNA precursor molecules are remodeled into functional sncRNAs [43].
Alternatively, piRNAs participate in a distinct process known as primary and secondary
piRNA biogenesis [21]. This process, which has been partially described and characterized
in Drosophila, is also conserved in C. elegans. The long, single-stranded piRNA precursor
molecules are derived from the transcripts of protein coding genes, transposons, tRNA,
rRNA, and intergenic loci [44–47] which possibly contributes to the targeted sequence
specificity observed in mature piRNAs. piRNAs mostly originate from repetitive sequences
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within the genome including transposable elements (TEs), which can be distributed in
clusters throughout the chromosomes on both DNA strands [4].
Primary piRNA biogenesis begins with transcription of single stranded piRNA progenitor molecules by RNA polymerase II, albeit recruitment mechanisms and promoter
regions remain elusive [48] constituting new areas of research. Processing of these precursors operates in a Dicer/Drosha independent manner. The single stranded piRNA
precursor molecules are shuttled out of the nucleus into Yb bodies, cytoplasmic membranesless organelles [49] (Figure 1). In the Yb bodies, the precursor piRNA/Piwi complex
interacts with TDRD, Armitage, Vreteno, and Sister of Yb proteins. The function of these
proteins during piRNA biogenesis remains elusive, however, they have been shown tso
colocalize to Yb bodies in Drosophila germline, suggesting that they play instrumental role
in piRNA biogenesis [50–55]. Yb bodies have been shown to be surrounded by mitochondria, facilitating the mitochondria membrane anchored endonuclease Zucchini to process
precursor piRNAs into smaller segments [51,56]. With the help of Shutdown (Shu) and
Heat shock protein 90 (Hsp90), piRNAs then complex with Piwi proteins [57,58]. Lastly,
the 30 end is processed by an unknown protein, after which the HENMT1 adds a methyl
group to the 20 carbon of the ribose on the 30 end of the transcript [40,59]. This modification
is crucial for piRNA stability [41]. Mature piRNA complexes can either reenter the nucleus
to induce transposon silencing and gene regulation or initiate secondary piRNA biogenesis,
also known as the ping pong cycle [4,60]. Interestingly, different piRNA subsets have
been shown to complex with different PIWI proteins. Piwi and Aubergine (Aub) have
a propensity for piRNA sequences that are specifically antisense to transposons with a
50 uridine. In contrast, Ago3 proteins bind to sense piRNAs containing adenine at the
10th nt position, with no preference for 50 U piRNA sequences [4,7,44,61] (Figure 1).
The ping-pong cycle which has been the major contributor of piRNA biogenesis, depends on Aub and Ago3 associated piRNAs. Once long, single stranded precursor piRNAs
are transcribed via RNA polymerase II, they are shuttled to the nuage, an electron-dense
phase separated granules anchored to the cytoplasmic face of the nuclear pore [60] TDRD
proteins may serve as scaffolds and initiators of ping pong cycle, as mutations within
these proteins disrupt piRNA biogenesis [56,62–64]. The amplification cycle involving
these PIWI proteins calls for mature 50 U piRNAs complexed with Aub to recognize specific complementary sequences within the transcript. Once complementarity between the
U:A nt is achieved, the Aub enacts endonucleolytic cleavage of the target piRNA at the
10th/11th nt of the sequence. This slicing activity generates the 50 end of a new sense
piRNA, including a 10 nt long 50 overlap with the initial antisense piRNA and an adenosine
residue at the 10th nt. Shu and Hsp89 are hypothesized to load the newly generated
piRNA onto Ago3 [57,58]. Subsequent trimming by an unidentified enzyme and 30 modification by piRNA methyltransferase finalizes piRNA maturation. The newly formed
complex then produces more antisense Aub-bound piRNAs from piRNA clusters within
the transcripts via the same biogenesis mechanism. The secondary piRNA amplification of
the ping pong cycle has been linked to targeted post-transcriptional gene silencing [4,61].
piRNA biogenesis from sense/antisense transposons has been defined but requires further
investigation [65]. However, others have shown that piRNAs derived from both mRNA
and lncRNA are typically generated from the 30 UTR but the mechanism is yet to be fully
unraveled. Noncanonical by-products of concurrent transcription of adjacent genes are also
thought to be piRNA precursor transcripts, which hail from dual-stranded clusters [66].
Though much of the piRNA biogenesis pathway is conserved amongst most organisms [67],
further studies are needed to fully elucidate mechanisms within the pathway (Figure 1).
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Figure 1. piRNA biogenesis Precursor piRNAs within the nuclear compartment are generated from sense and antisense
Figure 1. piRNA biogenesis Precursor piRNAs within the nuclear compartment are generated from sense and antisense transposon
transposon sequences, 30 UTR of messenger RNAs (mRNAs), ribosomal RNAs (rRNAs), long noncoding RNAs (lncRNAs)
sequences, 3′UTR of messenger RNAs (mRNAs), ribosomal RNAs (rRNAs), long noncoding RNAs (lncRNAs) and intergenic DNA
and sequences.
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then enact various piRNAs function in the nucleus and/or in the cytoplasm.
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2.2. Transposon Silencing
One of the earliest functions of piRNAs is their ability to serve as regulators of TE
movement throughout the genome. TEs can be randomly inserted throughout the genome,
causing changes in protein coding genes and regulatory sequences, which can affect gene
expression and cause the production of defective or malfunctioning proteins [68]. It is well
documented that piRNAs are vital to ensuring genomic integrity, as the piRNAs/Piwi
complex can monitor TE activity by silencing TEs post transcriptionally [69]. Mutations
within the germline have been shown to cause an increase in retrotransposons, which
causes the death of germ cells in conjunction with various deficiencies within microtubule
cytoskeletal polarization. Consequently, alterations in this conserved mechanism leads to
changes in polarized localization of specific proteins and mRNAs that are necessary for
oogenesis in Drosophila [70].
Sarot et al. illustrated that Piwi is required for silencing transposons within the
3am locus in gonadal somatic cells, which is a well-known active region [71]. A vast
number of piRNAs originate from transposon regions of the genome, as shown by others
and recently our group [37,65,72,73]. Several studies have demonstrated the importance
of PIWI proteins in the regulation of transposon silencing in Drosophila. For example,
aub-mutants illustrated increased transposon activity [70,74–77]. Similarly, Ago3 and
Aub are known to colocalize in the nuage for secondary piRNA biogenesis; mutations
within either of these proteins triggered defects in biogenesis and elevated transposon
transcripts [78]. The vital function of piRNAs in maintaining genome stability has been
illustrated using knockout models designed to understand the roles of PIWI proteins [8,79].
In germ cells of mili/miwi2 KO mice, Carmell et al. observed a significant increase in
transposable elements [79]. Transposon silencing remains a critical function of piRNAs,
however further studies should aim to describe the targeted action of piRNAs as well
uncover other mechanisms that can contribute to this silencing.
2.3. Epigenetic Regulation
piRNAs have been shown to participate in epigenetic regulation through two mechanisms: activation of sequence specific de novo methylation and chromatin remodeling.
Huang et al. demonstrated a vital role of the piRNA/Piwi interface in epigenetic programing in Drosophila. Once piRNA complementary sequences were introduced in ectopic
sites, several DNA binding proteins, including Piwi and heterochromatin protein 1 (HP1a),
induced increased H3K9me2/3 recruitment, which ultimately led to reduced RNA polymerase II enlistment. This finding supports the hypothesis that piRNAs are necessary for
the recruitment of epigenetic associated proteins to precise genomic regions/locations in
Drosophila [80,81]. Deletion of PIWI proteins in murine models significantly altered the epigenetic makeup throughout the genome [8,79]. Watanabe et al. demonstrated simultaneous
coactivation of piRNA-mediated DNA methylation and transcription of piRNA dependent
regions in mice. Retrotransposons in piRNA dependent regions and in piRNA clusters
were knocked out in a mouse model. The deleted regions were shown to play a role in the
initiation of piRNA-mediated methylation. These results showed the importance of MIWI
in determining chromatin structure through direct targeting of piRNAs to genomic regions,
which also has been observed in other organisms [82].
The synergic interactions between methyltransferases, histone modifying proteins,
chromatin remodeling proteins, and piRNA/Piwi complex is implicated in de novo methylation and subsequent suppression of TEs within the germline. However, the mechanism is not well understood and necessitates further investigation. In Drosophila, Piwi
has been shown to interact with chromosomes in somatic tissues, implicating its role in
inducing epigenetic modifications at various binding sites [81,83,84]. A study showed
that a piRNA/Piwi complex in Aplysia nerve cells promoted methylation of CpG islands
within the promoter region of transcription factor CREB2, further solidifying the role of
piRNA/PIWI complex in epigenetic gene regulation [85,86]. piRNA/Piwi complexes can
also recruit DNA methyltransferases to target CpG sites in non-TE protein coding regions,
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which alters transcriptional activity in mice [87]. Fu et al. demonstrated that genomic
regions neighboring differentially methylated CpG areas were fortified with sequence
matches to transfected piRNAs in somatic cancer cell lines [88]. This transcriptional repression can then possibly be inherited at the target sites in mammals, however further research
is needed to elucidate this fully. For example, overexpression of piR-021285 induced
methylation of ARHGAP11A at CpG site within the 50 UTR/first exon, which dampened
messenger RNA expression while simultaneously inhibiting breast cancer programmed
cell death [28]. Recent efforts to uncover mechanistic machinery of piRNA directed DNA
methylation in mammals have identified proteins essential to this function. SPOCD1 has
recently been identified as a MIWI2 associated protein that is required for TE silencing
via piRNA mediated methylation. Loss of Spocd1 induced infertility in male mice without
altering piRNA biogenesis or MIWI2 nuclear localization [89]. Similarly, recruitment of
TEX15 has been shown to be an executor of piRNA directed methylation, as TEX15 is
required for the nuclear function of MIWI2 [90]. Further research should delineate exact
mechanisms that trigger and induce piRNA/Piwi dependent methylation throughout the
genome. Inheritance of these piRNA induced epigenetic modifications should also be
explored in depth.
Although the mechanism of piRNAs induce methylation of genomic regions is unclear, studies have provided evidence indicating that piRNAs serve as guides for histone
modifying and chromatin remodeling proteins. Mohn et al. utilized chromatin immunoprecipitation to suggest that the ribonucleoprotein complex targets sequences within euchromatin via preliminary transcripts, while also targeting heterochromatin via RNA/DNA
interaction. This is a direct result of piRNA sequence complementarity, illustrating the
wide yet potentially specific target [18,91]. Piwi has been found to interact with HP1a
directly, and colocalization of these proteins has been observed on many sites throughout
chromosomes in Drosophila [80,81]. As regulators of the position effect variegation (PEV),
which decreases gene expression of euchromatin genes near heterochromatin sites, Piwi
and Aub can silence gene expression via heterochromatin assembly [83]. piRNA dependent
recruitment of histone modifying proteins remains a mystery, however current research
should continue to decode this mechanism.
2.4. Post-transcriptional and Translational Control
In several organisms, it has been shown that 30 UTRs of protein coding mRNAs are
sources for piRNA production in Drosophila, mice, and Xenopus, indicating that piRNAs
also can regulate mRNA turnover [92]. It was observed that VAS protein levels increased in
aub and ago3 mutants, which could possibly be attributed to decreased number of piRNAs
derived from vas mRNA [78,93]. Miwi proteins in mice have been shown to complex with
and stabilize mRNAs of genes necessary for post-meiotic steps of spermatogenesis [94].
Lee et al. showed that piRNAs could target non-transposon genes that contribute to the
regulation of spinal shape [95].
In terms of piRNA/mRNA interaction, piRNAs require base pairing at both the
2–11 nt at the 50 end of the piRNA as well as within the 12–21 nt of the sequence [28]. To
regulate mTOR expression, piR-55490 was observed to bind to the 30 UTR, initiating mRNA
degradation and muffle lung cancer development [25]. Esposito et al. concluded that testis
and brain specific piRNAs can regulate MTNR1A expression in human somatic cells [96].
piRNAs have also been shown to play a role in mRNA decay via deadenylation of the 30 end
of mRNA transcripts. In Drosophila, piRNA dependent degradation of maternal mRNA is
dependent upon Smg, deadenylase CCR4, and the piRNA/Piwi complex. Impaired piRNA
regulation induced transcript stabilization [97,98]. The post-transcriptional/translational
regulatory role of piRNAs outside of the germ line has yet to be fully understood, however
these studies strongly implicate piRNAs as critical post-transcriptional regulators.
Evidence of chromatin remodeling, de novo methylation, and direct transcriptional
regulation shows the multifaceted roles of piRNAs [28,37,68–83,85–91]. These processes
clearly classify piRNAs as regulators of gene expression in various capacities. Currently,
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little evidence implicates the piRNA/Piwi complex in translational regulation, however
several emerging reports indicate that PIWI proteins can interact with translational proteins [99–101]. For example, Grivna et al. showed that Miwi binds to eIF4E, the mRNA
50 cap binding protein essential for guidance to ribosomes in the cytoplasm and translational control [99]. A separate study reported that Mili/eIF3a complex interacts with
eIF4E/eIF4G 50 cap binding complex [101]. Recently, Ramat et al. reported that PIWI
protein Aub is required for translational activation of nanos mRNA, which is essential in
germ line survival and pluripotency. Through direct physical interaction, Aub complexes
with poly(A)-binding protein (PABP) and translation initiation factor eIF3. Using polysome
gradient profiling, Aub was shown to be essential for the initiation step of translation [100].
These studies suggest PIWI proteins potentially play a role in initiation and activation of
translation; however, further studies are needed to completely delineate the functions of
PIWI proteins and piRNAs in this process.
3. piRNAs vs other sncRNAs
Although piRNAs are the most newly identified class of sncRNAs, they are the least
classified. Hence, several research efforts have been geared towards delineating similarities
and differences between piRNAs and other sncRNAs, specifically miRNAs and siRNAs.
piRNAs are widely and differentially expressed in various tissues and cell types, but mostly
have been detected within the germ cells of mammals, fish, and Drosophila [102,103]. In
terms of biogenesis, it is well understood that piRNAs diverge significantly from miRNAs
and siRNAs. piRNAs are generated via RNaseIII-independent pathways and do not
involve dsRNA progenitors. Since these unique sncRNAs are generated from long single
stranded precursors, they show preferential cleavage at uridine residues and then complex
with PIWI proteins [65]. In contrast, siRNAs are processed by Dicer from small dsRNA
complexes with a distinct 2 nt 30 overhang and 50 phosphate group. miRNAs are transcribed
via RNA polymerase II from primary miRNA (pri-miRNA) precursors which contain stem
loop structure. These molecules undergo further processing that give rise to classical
miRNAs [104,105].
Structurally, miRNAs are short, single stranded noncoding RNAs, generally 20–24 nucleotides in length, which are encoded in eukaryotic cells and function in various signaling
pathways [106,107]. siRNAs, however, are 21–23 nt long RNA duplexes that interact and
activate the RNA-induced silencing complex (RISC) [108,109]. Functionally, miRNAs are
recognized for control of mRNA stability and translation. These sncRNAs are found within
the cytoplasm where they recognize and bind the 30 UTR of target mRNA complementary
sequences via the miRNA “seed sequence” located at their 50 end [110]. The consequence
of this interaction is either mRNA degradation or translational repression. In contrast,
siRNAs must accomplish 100% complementarity with mRNA target seqence in order to
enact repressive function [109].Though piRNAs and miRNAs can bind to various target
molecules, siRNAs are specific to one mRNA target and regulate expression exclusively
through endonucleolytic cleavage via RISC [109]. miRNAs are categorized via sequence
conservation and the seed sequence, meaning many miRNAs within the same family share
similar targets in intertwining signaling pathways [111]. Current research reveals untraditional roles of miRNAs within the nucleus, including transcriptional silencing/activation,
and alternative gene splicing [112–114]. We also recently showed the role of miRNA in
translation initiation [115]. Although the mechanisms which activate these noncanonical
roles remain to be fully understood, several debates regarding miRNA nuclear translocation persist [114]. Several studies have reported that miRNAs activate gene expression via
promoter region binding by utilizing sequence complementarity [112,116].
In contrast, piRNAs are about 24–31 nucleotides long and were discovered in Drosophila
mutants that underwent unequal division of stem cells within the germline. As the most
abundant sncRNAs [13,14], extensive research has begun to uncover the vast roles these
molecules play in cell homeostasis and disease. Developmentally, they are essential for
germ line survival and enact transposon silencing, actively maintaining genome integrity.
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Any defects and disruptions in piRNA biogenesis is detrimental, causing germline specific cell death and sterility via upregulation of transposon expression as seen in mice
and fish [117]. Other functions include conserving telomere structure, controlling RNA
silencing, and inducing epigenetic factors that alter chromatin structure. More recently,
studies have begun to investigate piRNA function in somatic cells, where expression seems
to be regulated in a tissue specific manner. Targeting of mRNA sequences is believed to be
similar to that of miRNAs, specifically utilization of the seed sequence. Unlike miRNA,
Piwi/piRNA complexes can also recruit other proteins such as CCR4-NOT and Smg to
create RISC like complexes called pi-RISCS, which repress mRNA translation via imperfect
base pairing [118,119]
For piRNAs to enact their gene silencing function, they must complex with a specific
subset of argonaute proteins called PIWI proteins. The association with Piwi and Dicer
independent mechanism are the main distinguishing factors between siRNAs and piRNAs.
However, similarly to other sncRNAs, piRNAs are loaded into the PIWI protein and
guide argonaute to target sequences using Watson-Crick base pairing and seed sequence
complementarity. When complementarity is reached, RNase H-fold activity of the PIWI
domain cleaves phosphodiester bond of two nucleotides in the target RNA that pair with
the 10th and 11th nt of the piRNA sequence [65]. In contrast, Dicer within RISC displays
RNaseIII activity, initiating two cuts which are 21–22 nt apart on the target sequence [120].
Post transcriptional functions of piRNA are poorly understood, and only a few reports
show different PIWI proteins complexing with mRNA 50 cap and eIF proteins to regulate
translation [99,101]. Extensive research is needed in this area to fully elucidate this potential
function. In contrast, miRNAs and siRNAs are known mediators of post transcriptional
regulation, and the pathways they regulate differ according to cell type, organism, and
argonaute protein binding. Argonaute proteins complexed with miRNAs or siRNAs utilize
slicer activity and/or slicer dependent mechanisms to employ repression functionality.
This includes inhibition of eIF4E cap binding and mobilization of other proteins that participate in translational repression and mRNA degradation [98,121]. High complementarity is
required for target mRNA degradation via slicing, mediated by degradation proteins such
as XRN1, exosomes and Ski complexes [122]. Translationally repressed RNAs can be degraded through deadenylation, decapping, and subsequent degradation in P-bodies [97,98].
Though many differences reside in biogenesis and many similarities reside in function of
sncRNAs, further studies are required to identify the unique roles that each of these RNAs
play in the regulation of gene expression.
4. The Role of piRNAs in Cardiomyopathies
It was previously thought that piRNAs expression was exclusive to germ cell lines, but
recent studies have shown that piRNAs are also expressed in non-germline cells [37,123].
In recent times, it has been theorized that piRNAs are expressed in higher eukaryotic
genomes. This theory came from the discovery that piRNAs regulate transposons and
higher eukaryotes house large repositories of transposable elements. Recent advances
indicate that piRNAs are found in the central nervous system, liver, cardiovascular system,
and in circulating serum exosomes [35,124]. Researchers have recently taken interest in the
role of piRNA expression in the differentiation of cardiomyocytes.
Greca et al. sought to investigate the role of piRNAs in the development of cardiac
progenitor cells. To examine this, the group analyzed RNA-seq data from H9 human
embryonic stem cells, early mesoderm progenitor cells and cardiomyocytes. Stem-loop
retrotranscription primers were generated to obtain cDNA from piRNAs of interest and real
time PCR was carried out to quantify piRNA expression. It should be noted that mapped
reads from mRNAs and other non-coding RNAs were filtered out by size to accurately
determine the role of piRNAs in the development of cardiac progenitor cells. The group
reported that there are at least 447 piRNAs involved in the progression of pluripotent stem
cells to cardiomyocytes. Furthermore, cardiac progenitor cells expressed increased levels
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of mitochondrial tRNA/rRNA derived piRNAs, followed by a significant upregulation in
HIWI2 expressing cells [123].
Since the majority of these piRNAs were derived from other types of RNAs, the
group noted that further validation must be performed to ensure their accurate classification. However, approximately 90 of the 447 piRNAs involved in the development of
cardiomyocytes originated from the mitochondrial genome [110]. It should be noted that
piRNAs were found to be uniformly scattered throughout the genome, aside from the
mitochondrial genome where they were expressed in clusters. RNA-seq data suggested
that nuclear encoded lncRNA MALAT1 and TTN encompass the highest number of piRNAs
in cardiac progenitor cells. RNA-seq data demonstrated that MALAT1-derived piRNAs
include piR-4403262, and piR-4424378. TTN-derived piRNAs include piR-1551388, piR4193743, and piR-2715002. Interestingly, the group reported that six times more piRNAs
were downregulated in cardiac progenitor cells compared to pluripotent stem cells. This
study showed that piRNAs are involved in cardiac cell differentiation and maturation, thus
dysregulation of piRNA can result into cardiac pathology [123].
Vella et al. also investigated the role of the piRNome, the global expression profile
of piRNAs within the cellular system, in different cardiac cell types using biopsies from
patients undergoing heart surgery. These biopsies were used to isolate cardiac progenitor
cells, which were grown as undifferentiated self-adherent 3D cultures in suspension (cardiospheres) or as adherent monolayers on a plate (cardiosphere-derived cells). They also
isolated cardiac fibroblasts from these biopsies and examined the piRNome among each of
these cell types via microarray analysis and RT-PCR validation. The group reported that
15,311 piRNAs were expressed in all three cell types, among the 23,000 piRNAs within the
dataset used for the study. Of the identified piRNAs, 641 were upregulated and 1381 were
downregulated in cardiospheres compared to cardiosphere-derived cells. However, there
were only 255 upregulated and 780 downregulated piRNAs in cardiospheres compared
to cardiac fibroblasts. Furthermore, when cardiosphere-derived cells were compared to
cardiac fibroblasts, only 52 piRNAs were upregulated and 129 were downregulated. These
findings suggest that piRNAs are differentially expressed in cardiac cells and have distinct functions in individual cell types. To further support this theory, the group reported
that certain piRNAs such as DQ570326 and DQ58246 are expressed at higher levels in
cardiosphere-derived cells compared to cardiospheres. Furthermore, some piRNAs, such
as DQ579896 and DQ581624 are upregulated in cardiac fibroblast but not cardiospheres or
cardiosphere-derived cells [125].
Di Giacomo et al. reported that the inhibition of LINE-1 retrotransposons was mediated by piRNAs [126], and this mechanism was shown to attenuate ischemic heart disease
via piRNA-mediated activation of AKT [127]. Vella et al. examined LINE targets of upregulated piRNAs in cardiospheres, cardiosphere-derived cells and cardiac fibroblasts and they
found that the upregulated piRNAs targeted all three classes of LINE reverse transcriptase:
LINE-1, LINE-2 and CR1. More specifically, the transcript levels of LINE-1 transcripts
were lower in cardiospheres and cardiosphere-derived cells compared to cardiac fibroblasts. This corresponded to increased expression of phosphorylated AKT in cardiospheres
and cardiac derived cells compared to cardiac fibroblast. It was also demonstrated that
piRNA-mediated phosphorylation of the Ser473 residue of AKT was associated with the
phosphorylation of the Ser9 residue of GSK3β to inactivate GSK3β’s kinase activity in
cardiospheres and cardiosphere derived cells. Hence, piRNA expression is associated
with cardiac regeneration and mediated by AKT-mediated phosphorylation. However, it
is possible that cardiac piRNA expression has downstream effects on cellular signaling
pathways that involve GSK3β, which is a known repressor of cardiac hypertrophy by phosphorylating proteins involved in cell proliferation such as β-catenin and NFATC4 [128].
Overall, this study showed that the piRNome may play a role in regeneration within
cardiac progenitor cells—indicating that piRNAs may be involved in cardiac pathogenesis
and may serve as therapeutic targets [125].
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In 2020, Gao et al. investigated the potential role of piRNAs in cardiac hypertrophy by
examining the global expression of piRNAs in mice. Samples were obtained from the left
ventricle 4 weeks after a transverse aortic construction surgery, then subjected to microarray
analysis. The group found that piR-141981, piR-6999 and piR-110550 were increased but
piR-13375 and piR-106654 were decreased in mice that underwent a transverse aortic
construction surgery versus a placebo/sham surgery. Of these piRNAs, piR-141981, piR110550 and piR-13375 increased mRNA expression of β-myosin heavy chain, a cardiac
stress marker and biomarker of cardiac hypertrophy. The group also examined the global
expression of these three piRNAs and found that piR-141981 was expressed at higher levels
in the heart, compared to other organs [22].
Since piR-141981 was previously unclassified, the group named it the cardiachypertrophy-associated piRNA (CHAPIR). CHAPIR was found to be expressed at higher
levels in cardiomyocytes compared to cardiac fibroblasts. In mice, CHAPIR is located
on chromosome 4 within intron 1 of Gm12648. The group generated CHAPIR knockout
mice to observe the role of this piRNA in the development of hypertrophy following
traverse aortic construction surgery. They found that a deficiency of CHAPIR blocked the
development of cardiac hypertrophy following surgery. This was mediated through the
attenuation of hypertrophic biomarkers including the expression of Anp, Myh7 and Bnp. It
should be noted that Anp and Bnp encode atrial and brain natriuretic protein, respectively.
Myh7 encodes the heavy β-myosin chain [22]. The group found that CHAPIR increases the
stability of Parp10 mRNA transcripts by inhibiting METTL3-mediated N6-methyladenosine
methylation of Parp10 mRNA. More specifically, Parp10 gene expression is upregulated
when the CHAPIR-PIWIL4 complex interacts with METTL3, blocking N6-methyladenosine
(m6A) methylation of Parp10 mRNA transcripts. Under “normal” conditions, m6A destabilizes Parp10 mRNA transcripts and accelerates their degradation. However, in the presence
of CHAPIR, Parp10 mRNA is translated into PARP10, which inactivates GSK3β through
mono-ADP-ribosylation. Inhibition of GSK3β kinase activity then leads to the onset of
hypertrophy, marked by nuclear accumulation of NFATC4. Under “normal” conditions
NFATC4 is phosphorylated by activated GSK3β—promoting its nuclear export and decreased hypertrophic response. However, when GSK3β’s kinase activity is inhibited it
cannot phosphorylate NFATC4, which remains in the nucleus—promoting cardiac hypertrophy. This finding supports the theory that piRNA activity may be associated with
cardiomyopathies since cardiac progenitor cells do not express large amounts of piRNAs
under normal conditions [22].
Furthermore, Yang et al. demonstrated that exosomal piRNAs have the potential
to serve as biomarkers in patients with heart failure. The group isolated exosomes from
the blood of heart failure patients and age matched controls. RNA was isolated from the
exosomes and the expression of piRNAs was examined using RNA-seq. They reported
that approximately 585 piRNAs were upregulated and 4623 were downregulated in the
exosomes of patients with heart failure. Furthermore, has-piR-006426 and has-piR-0200009
were among the most downregulated piRNAs derived from the serum exosomes of heart
failure patients. These findings indicate that hsa-piR-006426 which is located on chromosome 17p11.2 and has-piR-0200009, which is located on chromosome 7q35 may be involved
in heart failure and may serve as clinically relevant biomarkers for heart disease [23]. In
a separate study, Rajan et al. discovered that PiR_2106027 was elevated in the serum of
patients with Troponin-I negative myocardial infarctions and downregulated in healthy
patients. Hence, PiR_2106027 may serve as a biomarker for myocardial infarctions [24].
Furthermore, recent studies suggest a correlation between piRNAs, mTOR and cardiac
tissue regeneration. Specifically, piR-55490 has been shown to regulate mTOR, which consequently promotes angiogenesis and cardiac tissue regeneration. This suggest that piRNAs
may regulate both cancer and cardiovascular disease/regeneration in an mTOR-dependent
manner [25,26].
Overall, these studies suggest that piRNA expression differs among cardiac progenitor
cells and cardiac fibroblasts, suggesting that piRNAs may play distinct roles in different
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types of cells. Furthermore, cardiac progenitor cells tend to express downregulated levels of
piRNAs compared to other cardiac cells such as cardiac fibroblasts. However, the dysregulation of specific piRNAs, such as CHAPIR promotes the development of cardiomyopathies,
including cardiac hypertrophy. Furthermore, other piRNAs such as has-piR-0200009 may
serve as clinically relevant biomarkers of cardiomyopathies and heart failure. Although
the exact function of piRNAs in the progression of cardiomyopathies remain to be fully
elucidated, current research suggest that piRNAs may serve as therapeutic targets and
clinically relevant biomarkers.
5. Influence of piRNAs in Cancer Pathogenesis
It has been found that PIWI proteins in human and mice, such as PIWIL1, PIWIL2,
PIWIL2 proteins, and HIWI are expressed in various types of tumor cells [129,130]. PIWIL1
overexpression is associated with cell cycle control and proliferation [130] while PIWI2
has roles in anti-apoptotic signaling [131]. Dysregulated expression of piRNAs has been
reported in human cancers, including gastric, bladder, breast, colorectal and lung cancer.
These findings indicate that the piRNA dysregulation may be linked to cancer development,
onset and progression. The potential role of piRNAs in cancer has just emerged and requires
investigation. Although the functional roles of specific piRNAs is poorly understood in
human cancer, the following findings implicate piRNA mediated regulation as an important
focus for cancer research.
5.1. Breast Cancer
Breast cancer is one of the most common types of cancers and is second only to lung
cancer for cancer related deaths in women. Numerous piRNAs have been found to play
a role in this disease. Analysis of RNA sequences from breast cancer cells versus normal
tissues showed differential expression of piR-4987, piR-20485, piR-20582, and piR-20365.
Of these, upregulated piR-4987 was associated with lymph node metastasis of breast
cancer [28]. Another study found that piR-021285 can methylate several genes related to
breast cancer in cell culture studies [27]. Anti-cancer effects were also observed with piRNA.
For example, piR-36712 was shown to exhibit tumor suppressor effects by increasing the
efficacy of paclitaxel and doxorubicin using animal model of breast cancer [132]. piRDQ598677 is downregulated in cancer. When overexpressed, breast cancer growth is
inhibited through increased degradation of mRNA for TAX1BP, TNFESF10B, and SFRP2
which have preestablished roles in tumorigenesis [27,28,132,133].
5.2. Lung Cancer
Lung cancer is the number one cause of cancer-related death worldwide. One study
demonstrated that in human bronchial epithelial cells, piR-L-163 was upregulated upon
cisplatin treatment in vitro and in vivo. This piRNA is capable of regulating ezrin-radixinmoesin (ERM) proteins which have altered expression during cancer progression [29].
piR-651 can act as an inhibitor of apoptosis in human lung cancer cells. Inhibition of
this piRNA increased expression of pro-apoptotic caspases, attenuating tumor growth.
When upregulated, piR-651 is believed to promote upregulation of cyclins and CDKs to
increase cell proliferation. piR-55490 is capable of binding mTOR, inhibiting the protein
and reducing expression of its target genes HIF-1, PGC-1α, and PPARγ. In treatment with
this piRNA, a decrease in lung cancer cell proliferation was observed [25,134].
5.3. Colorectal Cancer
Colorectal cancer is one of the most common cancers in both men and women and the
third most common cause of mortality. One research group has implicated piR-823 as a
factor in colorectal cancer when they showed knocking down of this piRNA induced G1
arrest and suppressed inhibition of apoptosis in colorectal cells. It was suggested that piR823 promotes carcinogenesis through interaction with HSF1, which can regulate heat shock
protein expression and is often overexpressed in highly malignant cancers [135,136]. Col-
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orectal cancer tumor growth and metastasis was found to be enhanced by increased levels
of oncogenic piR-1245 which is capable of binding and subsequently suppressing multiple
tumor suppressors such as ATF3, DUSP1, and SESN2 by degradation of mRNA. Histologically, colorectal cancer cells with elevated piR-1245 were more poorly differentiated and
exhibited higher metastatic potential [31].
5.4. Gastric Cancer
piRNAs 823 and 651 were also shown to have a role in gastric cancer where treatment
with piR-823 inhibited cancer growth in vivo and piR-651 overexpression was associated
with metastasis. One group proposed that these piRNAs could be biomarkers for early
diagnosis similar to serum carcinoembryonic antigen (CEA). This idea is a point of significant interest, as piRNA does not degrade as readily as these other makers and is easier to
detect. piRNA 823 has also been associated with worse prognosis in patients with multiple
myeloma, via regulation of de novo DNA methylases DNMT3A, 3B and angiogenesis [32].
The piRNA pathway has been found to be required for de novo methylation of murine
Rasgrf1 gene. Aberrant methylation of the differentially methylated region of Rasgrf1 is
associated with an increased risk of gastric cancer [137]. PIWI proteins can also regulate
the progression of gastric cancer in a piRNA independent manner via UPF1 mediated
nonsense mediated mRNA decay (NMD) mechanism [138].
5.5. Bladder Cancer
Transcript profiling of bladder cancer tissues implicated piRNA-DQ594040 as downregulated in bladder cancer. Subsequent in vitro experiments on human bladder cancer cell
lines indicated that overexpression of this piRNA led to inhibition of apoptosis and colony
formation, possibly through regulation of Tumor Necrosis Factor Superfamily Member
4 (TNFSF4) [33].
5.6. Liver Cancer
In relation to hepatocellular carcinoma (HCC), piR-Hep1 was found to be upregulated
in several HCC tissues. Upon silencing of this piRNA, a decrease in cancer viability and
invasion was observed. It is believed that piR-Hep1 upregulates PI3K/AKT signaling.
Additionally, though its role in cancer has not been elucidated, significant elevations in
piR 013306 are specific to liver cancer, meaning it could serve as a novel biomarker [33,35]
which require further investigation to harness its importance in HCC.
5.7. Melanoma
Though no specific piRNA have been associated with melanoma, aberrations in PIWIpiRNA pathway proteins such as PIWIL3 and DCP1A are predictors of more aggressive
forms of this cancer [139].
5.8. Glioblastoma
PIWIL3 expression has been shown to have a direct correlation with glioblastoma
aggressiveness, both in terms of growth and metastasis. It was also reported that downregulation of PIWIL3 reduced progression of gastric cancer through JAK2/STAT3 signaling.
piR-30188 can act as a tumor suppressor through miR-367-3p regulation. piR-8041, normally downregulated in glioblastoma, can suppress cancer growth when upregulated
through regulation of MAPK signaling and heat shock protein expression. piRNAs were
also seen to be of use in therapeutic delivery, where piRNA-DQ593109 promotes drug
delivery in the glial tumor microenvironment [140–142].
5.9. Pancreatic Cancer
Little is known about the role of piRNA in pancreatic cancer. Currently, RNAseq of pancreatic ductal adenocarcinoma tissue revealed significant downregulation of
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piR-017061, located within sno-HBII-296A. Additionally, piR-016658, piR-001311 (PV) have
been detected in the extracellular RNA of pancreatic cancer patients [36].
6. piRNAs and Infectious Diseases
The role of piRNAs in infectious diseases research remains to be elucidated. Current
piRNA studies in infectious diseases have been modeled in arthropods and nematodes.
These studies indicate that infections can induce aberrant expression of TEs in somatic
tissues [143,144]. This finding suggests that infections can significantly influence genome
stability, host gene transcription, splicing, and/or RNA editing [73].
Small RNA-induced regulation has been reported to be the primary antiviral defense
mechanism in nonvertebrate organisms [145,146]. In Caenorhabditis elegans, piRNAs were
shown to be dysregulated in response to changes in environmental conditions and infection: increased temperature downregulated piRNA expression whereas bacterial infection
led to upregulation of piRNA expression profile. These changes in piRNA expression
were multigenerational, despite removal of the stimuli—suggesting epigenetic regulation [144]. In Anopheles gambiae, piRNAs and siRNAs were profiled and found to have
increased expression under stress. The upregulated piRNAs were derived from both
genic and TE-associated regions of the genome [73]. Furthermore, studies in Drosophila
suggested a possible interplay between host siRNA and piRNA response mechanisms
and that the piRNA and siRNA pathways may regulate the same RNA substrates [143].
Others suggested that the piRNA pathway works in concert with the siRNA pathway to
inhibit viral replication in mosquitos [147]. Considering this intricate relationship between
these small RNAs during response to infection, it becomes evident that more work is
required to identify and characterize the possible synergistic interaction between these two
pathways [73].
Arthropod genomes contain sequences derived from integrations of DNA and nonretroviral RNA viruses. These sequences, known as endogenous viral elements (EVEs), are
acquired evolutionarily through past viral infections. Studies have implicated these EVEs
as templates for the biogenesis of piRNAs in several mosquito species and cell lines [148].
Host immune response to these integrated viral elements has been found to be associated with PIWI4. PIWI4 is involved in EVE-derived piRNA maturation and preferential
binding to piRNAs that are antisense to a given viral genome, which function to inhibit
viral replication. For example, a study on the response of piRNAs to gammaretrovirus in
koalas suggests that piRNAs mount both innate and adaptive immune response to viral
genome integration [149]. These studies give critical insights that initiate uncovering the
mechanisms of viral immune responses developed over time across different species.
Studies detailing the significance of piRNA in infectious diseases beyond viral infections remain limited. Recently, a group showed that piR-27283 upregulated in human skin
tissues infected with Mycobacterium leprae could serve as a potential biomarker of disease.
They further implicated piRNAs as possible determinants of macrophage function and
nerve regeneration through interactions with IL6R and GAS6 [150].
Trypanosoma cruzi, the causative agent of Chagas heart disease, can infect all nucleated
cells of the body. During the process of infection, the parasite induces significant changes
in the gene expression profiles of the host cells [37,151–153] through unknown mechanisms.
To elucidate the mechanisms by which the parasite dysregulates host gene expression
profile during the early phase of infection, our group challenged primary human cardiomyocytes with the parasite for 1 and 2 h, and purified the small RNAs for RNA-sequencing.
We observed that 207 known and novel piRNAs were dysregulated after 1- and 2-h following T. cruzi challenge. Though hundreds of piRNAs were dysregulated during the
early phase of infection, we were interested in the piRNAs that can target mRNAs that
could be important in T. cruzi infection and pathogenesis. Our analysis showed that some
dysregulated novel piRNAs targeted TGFβ, a known profibrotic cytokine that is upregulated during T. cruzi infection and suggested to play a role in T. cruzi induced fibrotic
pathophysiology [154–156]. FOS, a transcription factor belonging to the AP-1 family, is
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Functional
studies and characterization of these novel piRNAs reported by our group will strengthen the role of
piRNAs in T. cruzi pathogenesis. Evaluation of piRNA expression profiles in the context
of host-parasite interactions has the potential to delineate their molecular functions and
pathophysiological importance during infection and pathogen induced pathogenesis [37].
7. Conclusions
piRNAs and PIWI proteins have been regarded as guardians of the germline, as
they protect the genome from TEs. Accumulating evidence denotes piRNAs as vital
regulators of important cellular processes conserved among various organisms. This has led
investigators to consider potential noncanonical roles of piRNAs. The mechanisms through
which piRNAs contribute to various disease pathogenesis remain unknown and elusive.
However, studies are consistently implicating various important roles for piRNAs outside
of the germline. Further characterization of piRNA function is required to understand
how these sncRNAs regulate gene expression in a multitude of circumstances within the
host. Limitations of piRNA validation can be overcome with high quality RNA-sequencing
approaches. As our understanding of piRNA biology and function increases, so will the
availability of assays/experiments to uncover the exact mechanisms of piRNA function;
how many piRNAs targeting a gene of interest are required to carry out a specific function,
how are piRNAs targeting genes that function differently in different conditions regulated.
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These types of conceptual studies will provide critical insights into piRNAs as disease
biomarkers and modulators of gene expression.
Author Contributions: Conceptualization, P.N.N., S.M., K.J.R. and A.C.; resources, P.N.N., F.V. and
M.F.L.; writing—original draft preparation, K.J.R., A.C., J.T.R., G.R., A.A. and S.P.; writing—review
and editing, P.N.N., S.M., K.J.R., A.C., J.T.R., M.F.L.; visualization, K.J.R. and A.C.; supervision, P.N.N.
and S.M.; funding acquisition, P.N.N., and Meharry Medical College. All authors have read and
agreed to the published version of the manuscript.
Funding: This work is supported by NIH grants 1SC1AI127352, 5R25GM059994 and U54MD007586.
Conflicts of Interest: The authors declare no conflict of interest.

References
1.
2.
3.
4.
5.
6.

7.
8.
9.

10.

11.

12.
13.
14.
15.

16.
17.
18.
19.
20.

Farazi, T.A.; Juranek, S.A.; Tuschl, T. The growing catalog of small RNAs and their association with distinct Argonaute/Piwi
family members. Development 2008, 135, 1201–1214. [CrossRef] [PubMed]
Leung, Y.Y.; Kuksa, P.P.; Amlie-Wolf, A.; Valladares, O.; Ungar, L.H.; Kannan, S.; Gregory, B.D.; Wang, L.-S. DASHR: Database of
small human noncoding RNAs. Nucleic Acids Res. 2015, 44, D216–D222. [CrossRef]
Fang, Z.; Du, R.; Edwards, A.; Flemington, E.K.; Zhang, K. The Sequence Structures of Human MicroRNA Molecules and Their
Implications. PLoS ONE 2013, 8, e54215. [CrossRef] [PubMed]
Brennecke, J.; Aravin, A.A.; Stark, A.; Dus, M.; Kellis, M.; Sachidanandam, R.; Hannon, G.J. Discrete Small RNA-Generating Loci
as Master Regulators of Transposon Activity in Drosophila. Cell 2007, 128, 1089–1103. [CrossRef]
Murchison, E.P.; Kheradpour, P.; Sachidanandam, R.; Smith, C.; Hodges, E.; Xuan, Z.; Kellis, M.; Grutzner, F.; Stärk, A.;
Hannon, G.J. Conservation of small RNA pathways in platypus. Genome Res. 2008, 18, 995–1004. [CrossRef]
Juliano, C.E.; Reich, A.; Liu, N.; Götzfried, J.; Zhong, M.; Uman, S.; Reenan, R.A.; Wessel, G.M.; Steele, R.E.; Lin, H. PIWI proteins
and PIWI-interacting RNAs function in Hydra somatic stem cells. Proc. Natl. Acad. Sci. USA 2013, 111, 337–342. [CrossRef]
[PubMed]
Vagin, V.V.; Sigova, A.A.; Li, C.; Seitz, H.; Gvozdev, V.; Zamore, P.D. A Distinct Small RNA Pathway Silences Selfish Genetic
Elements in the Germline. Science 2006, 313, 320–324. [CrossRef] [PubMed]
Aravin, A.A.; Sachidanandam, R.; Girard, A.; Fejes-Toth, K.; Hannon, G.J. Developmentally Regulated piRNA Clusters Implicate
MILI in Transposon Control. Science 2007, 316, 744–747. [CrossRef]
Aravin, A.A.; Sachidanandam, R.; Bourc’His, D.; Schaefer, C.; Pezic, D.; Toth, K.F.; Bestor, T.; Hannon, G.J. A piRNA Pathway
Primed by Individual Transposons Is Linked to De Novo DNA Methylation in Mice. Mol. Cell 2008, 31, 785–799. [CrossRef]
[PubMed]
Roovers, E.F.; Rosenkranz, D.; Mahdipour, M.; Han, C.-T.; He, N.; Lopes, S.M.C.D.S.; Van der Westerlaken, L.A.; Zischler, H.;
Butter, F.; Roelen, B.A.; et al. Piwi Proteins and piRNAs in Mammalian Oocytes and Early Embryos. Cell Rep. 2015, 10, 2069–2082.
[CrossRef]
Praher, D.; Zimmermann, B.; Genikhovich, G.; Columbus-Shenkar, Y.; Modepalli, V.; Aharoni, R.; Moran, Y.; Technau, U.
Characterization of the piRNA pathway during development of the sea anemone Nematostella vectensis. RNA Biol. 2017, 14,
1727–1741. [CrossRef]
Gainetdinov, I.; Skvortsova, Y.; Kondratieva, S.; Funikov, S.; Azhikina, T. Two modes of targeting transposable elements by piRNA
pathway in human testis. RNA 2017, 23, 1614–1625. [CrossRef] [PubMed]
Peng, J.C.; Lin, H. Beyond transposons: The epigenetic and somatic functions of the Piwi-piRNA mechanism. Curr. Opin. Cell
Biol. 2013, 25, 190–194. [CrossRef]
Kozomara, A.; Griffiths-Jones, S. miRBase: Annotating high confidence microRNAs using deep sequencing data. Nucleic Acids
Res. 2014, 42, D68–D73. [CrossRef]
Song, J.-J.; Liu, J.; Tolia, N.H.; Schneiderman, J.; Smith, S.K.; Martienssen, R.A.; Hannon, G.J.; Joshua-Tor, L. The crystal structure
of the Argonaute2 PAZ domain reveals an RNA binding motif in RNAi effector complexes. Nat. Struct. Mol. Biol. 2003, 10,
1026–1032. [CrossRef] [PubMed]
Parker, J.S.; Roe, S.M.; Barford, D. Crystal structure of a PIWI protein suggests mechanisms for siRNA recognition and slicer
activity. EMBO J. 2004, 23, 4727–4737. [CrossRef]
Cheng, E.-C.; Kang, D.; Wang, Z.; Lin, H. PIWI Proteins Are Dispensable for Mouse Somatic Development and Reprogramming
of Fibroblasts into Pluripotent Stem Cells. PLoS ONE 2014, 9, e97821. [CrossRef]
Ross, R.J.; Weiner, M.M.; Lin, H. PIWI proteins and PIWI-interacting RNAs in the soma. Nat. Cell Biol. 2014, 505, 353–359.
[CrossRef] [PubMed]
Qiao, D.; Zeeman, A.-M.; Deng, W.; Looijenga, L.H.J.; Lin, H. Molecular characterization of hiwi, a human member of the piwi
gene family whose overexpression is correlated to seminomas. Oncogene 2002, 21, 3988–3999. [CrossRef] [PubMed]
Kuramochi-Miyagawa, S.; Kimura, T.; Yomogida, K.; Kuroiwa, A.; Tadokoro, Y.; Fujita, Y.; Sato, M.; Matsuda, Y.; Nakano, T. Two
mouse piwi-related genes: Miwi and mili. Mech. Dev. 2001, 108, 121–133. [CrossRef]

Int. J. Mol. Sci. 2021, 22, 2373

21.
22.

23.
24.

25.
26.
27.
28.
29.

30.
31.

32.

33.
34.

35.

36.

37.

38.
39.
40.
41.

42.
43.
44.

17 of 22

Mani, S.R.; Juliano, C.E. Untangling the web: The diverse functions of the PIWI/piRNA pathway. Mol. Reprod. Dev. 2013, 80,
632–664. [CrossRef] [PubMed]
Gao, X.-Q.; Zhang, Y.-H.; Liu, F.; Ponnusamy, M.; Zhao, X.-M.; Zhou, L.-Y.; Zhai, M.; Liu, C.-Y.; Li, X.-M.; Wang, M.; et al. The
piRNA CHAPIR regulates cardiac hypertrophy by controlling METTL3-dependent N6-methyladenosine methylation of Parp10
mRNA. Nat. Cell Biol. 2020, 22, 1–13. [CrossRef] [PubMed]
Yang, J.; Xue, F.-T.; Li, Y.-Y.; Liu, W.; Zhang, S. Exosomal piRNA sequencing reveals differences between heart failure and healthy
patients. Eur. Rev. Med. Pharmacol. Sci. 2018, 22, 7952–7961. [PubMed]
Rajan, K.S.; Velmurugan, G.; Gopal, P.; Ramprasath, T.; Babu, D.V.; Krithika, S.; Jenifer, Y.C.; Freddy, A.; William, G.; Kalpana, K.;
et al. Abundant and Altered Expression of PIWI-Interacting RNAs during Cardiac Hypertrophy. Heart Lung Circ. 2016, 25,
1013–1020. [CrossRef]
Peng, L.; Song, L.; Liu, C.; Lv, X.; Li, X.; Jie, J.; Zhao, D.; Li, D. piR-55490 inhibits the growth of lung carcinoma by suppressing
mTOR signaling. Tumor Biol. 2015, 37, 2749–2756. [CrossRef] [PubMed]
Chong, Z.Z.; Shang, Y.C.; Maiese, K. Cardiovascular Disease and mTOR Signaling. Trends Cardiovasc. Med. 2011, 21, 151–155.
[CrossRef] [PubMed]
Huang, G.; Hu, H.; Xue, X.; Shen, S.; Gao, E.; Guo, G.; Shen, X.; Zhang, X. Altered expression of piRNAs and their relation with
clinicopathologic features of breast cancer. Clin. Transl. Oncol. 2012, 15, 563–568. [CrossRef] [PubMed]
Fu, A.; Jacobs, D.I.; Hoffman, A.E.; Zheng, T.; Zhu, Y. PIWI-interacting RNA 021285 is involved in breast tumorigenesis possibly
by remodeling the cancer epigenome. Carcinogenesis 2015, 36, 1094–1102. [CrossRef]
Mei, Y.; Wanh, Y.; Kumari, P.; Shetty, A.C.; Clark, D.; Gable, T.; MacKerell, A.D.; Ma, M.Z.; Weber, D.J.; Yang, A.J.; et al. A
piRNA-like small RNA interacts with and modulates p-ERM proteins in human somatic cells. Nat. Commun. 2015, 6, 7316.
[CrossRef]
Yao, J.; Wang, Y.W.; Fang, B.B.; Zhang, S.J.; Cheng, B.L. piR-651 and its function in 95-D lung cancer cells. Biomed. Rep. 2016, 4,
546–550. [CrossRef]
Weng, W.; Liu, N.; Toiyama, Y.; Kusunoki, M.; Nagasaka, T.; Fujiwara, T.; Wei, Q.; Qin, H.; Lin, H.; Ma, Y.; et al. Novel evidence
for a PIWI-interacting RNA (piRNA) as an oncogenic mediator of disease progression, and a potential prognostic biomarker in
colorectal cancer. Mol. Cancer 2018, 17, 1–12. [CrossRef]
Yan, H.; Wu, Q.-L.; Sun, C.-Y.; Ai, L.-S.; Deng, J.; Zhang, L.; Chen, L.; Chu, Z.-B.; Tang, B.; Wang, K.; et al. piRNA-823 contributes
to tumorigenesis by regulating de novo DNA methylation and angiogenesis in multiple myeloma. Leukemia 2014, 29, 196–206.
[CrossRef] [PubMed]
Chu, H.; Hui, G.; Yuan, L.; Shi, D.; Wang, Y.; Du, M.; Zhong, D.; Ma, L.; Tong, N.; Qin, C.; et al. Identification of novel piRNAs in
bladder cancer. Cancer Lett. 2015, 356, 561–567. [CrossRef]
Rizzo, F.; Rinaldi, A.; Marchese, G.; Coviello, E.; Sellitto, A.; Cordella, A.; Giurato, G.; Nassa, G.; Ravo, M.; Tarallo, R.; et al.
Specific patterns of PIWI-interacting small noncoding RNA expression in dysplastic liver nodules and hepatocellular carcinoma.
Oncotarget 2016, 7, 54650–54661. [CrossRef] [PubMed]
Law, P.T.-Y.; Qin, H.; Ching, A.K.-K.; Lai, K.P.; Na Co, N.; He, M.; Lung, R.W.-M.; Chan, A.W.-H.; Chan, T.-F.; Wong, N. Deep
sequencing of small RNA transcriptome reveals novel non-coding RNAs in hepatocellular carcinoma. J. Hepatol. 2013, 58,
1165–1173. [CrossRef]
Müller, S.; Raulefs, S.; Bruns, P.; Afonso-Grunz, F.; Plötner, A.; Thermann, R.; Jäger, C.; Schlitter, A.M.; Kong, B.; Regel, I.;
et al. Next-generation sequencing reveals novel differentially regulated mRNAs, lncRNAs, miRNAs, sdRNAs and a piRNA in
pancreatic cancer. Mol. Cancer 2015, 14, 1–18. [CrossRef]
Rayford, K.J.; Cooley, A.; Arun, A.; Rachakonda, G.; Kleschenko, Y.; Villalta, F.; Pratap, S.; Lima, M.F.; Nde, P.N. Trypanosoma cruzi
Modulates PIWI-Interacting RNA Expression in Primary Human Cardiac Myocytes during the Early Phase of Infection. Int. J.
Mol. Sci. 2020, 21, 9439. [CrossRef] [PubMed]
Liu, P.; Dong, Y.; Xiao-Guang, C.; Puthiyakunnon, S.; Wu, Y.; Chen, X.-G. Developmental piRNA profiles of the invasive vector
mosquito Aedes albopictus. Parasites Vectors 2016, 9, 1–15. [CrossRef]
Kirino, Y.; Mourelatos, Z. Mouse Piwi-interacting RNAs are 2’-O-methylated at their 3’ termini. Nat. Struct. Mol. Biol. 2007, 14,
347–348. [CrossRef] [PubMed]
Saito, K.; Sakaguchi, Y.; Suzuki, T.; Siomi, H.; Siomi, M.C. Pimet, the Drosophila homolog of HEN1, mediates 2’-O-methylation of
Piwi-interacting RNAs at their 3’ ends. Genes Dev. 2007, 21, 1603–1608. [CrossRef] [PubMed]
Lim, S.L.; Qu, Z.P.; Kortschak, D.R.; Lawrence, D.M.; Geoghegan, J.; Hempfling, A.L.; Bergmann, M.; Goodnow, C.C.;
Ormandy, C.J.; Wong, L.; et al. HENMT1 and piRNA Stability Are Required for Adult Male Germ Cell Transposon Repression
and to Define the Spermatogenic Program in the Mouse. PLoS Genet. 2015, 11, e1005620.
Weick, E.-M.; Miska, E.A. piRNAs: From biogenesis to function. Development 2014, 141, 3458–3471. [CrossRef] [PubMed]
Welker, N.C.; Pavelec, D.M.; Nix, D.A.; Duchaine, T.F.; Kennedy, S.; Bass, B.L. Dicer’s helicase domain is required for accumulation
of some, but not all, C. elegans endogenous siRNAs. RNA 2010, 16, 893–903. [CrossRef] [PubMed]
Saito, K.; Nishida, K.M.; Mori, T.; Kawamura, Y.; Miyoshi, K.; Nagami, T.; Siomi, H.; Siomi, M.C. Specific association of Piwi with
rasiRNAs derived from retrotransposon and heterochromatic regions in the Drosophila genome. Genes Dev. 2006, 20, 2214–2222.
[CrossRef] [PubMed]

Int. J. Mol. Sci. 2021, 22, 2373

45.

46.
47.
48.
49.
50.
51.
52.
53.
54.

55.

56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.

67.
68.
69.
70.
71.
72.

18 of 22

Aravin, A.; Gaidatzis, D.; Pfeffer, S.; Lagos-Quintana, M.; Landgraf, P.; Iovino, N.; Morris, P.; Brownstein, M.J.; KuramochiMiyagawa, S.; Nakano, T.; et al. A novel class of small RNAs bind to MILI protein in mouse testes. Nat. Cell Biol. 2006, 442,
203–207. [CrossRef]
Girard, A.; Sachidanandam, R.; Hannon, G.J.; Carmell, M.A. A germline-specific class of small RNAs binds mammalian Piwi
proteins. Nat. Cell Biol. 2006, 442, 199–202. [CrossRef]
Grivna, S.T.; Beyret, E.; Wang, Z.; Lin, H. A novel class of small RNAs in mouse spermatogenic cells. Genes Dev. 2006, 20,
1709–1714. [CrossRef]
Gu, W.; Lee, H.-C.; Chaves, D.A.; Youngman, E.M.; Pazour, G.J.; Conte, D.; Mello, C.C. CapSeq and CIP-TAP Identify Pol II Start
Sites and Reveal Capped Small RNAs as C. elegans piRNA Precursors. Cell 2012, 151, 1488–1500. [CrossRef]
Hirakata, S.; Ishizu, H.; Fujita, A.; Tomoe, Y.; Siomi, M.C. Requirements for multivalent Yb body assembly in transposon silencing
in Drosophila. EMBO Rep. 2019, 20, e47708. [CrossRef]
Qi, H.; Watanabe, T.; Ku, H.-Y.; Liu, N.; Zhong, M.; Lin, H. The Yb Body, a Major Site for Piwi-associated RNA Biogenesis and a
Gateway for Piwi Expression and Transport to the Nucleus in Somatic Cells. J. Biol. Chem. 2011, 286, 3789–3797. [CrossRef]
Saito, K.; Ishizu, H.; Komai, M.; Kotani, H.; Kawamura, Y.; Nishida, K.M.; Siomi, H.; Siomi, M.C. Roles for the Yb body
components Armitage and Yb in primary piRNA biogenesis in Drosophila. Genes Dev. 2010, 24, 2493–2498. [CrossRef]
Haase, A.D.; Fenoglio, S.; Muerdter, F.; Guzzardo, P.M.; Czech, B.; Pappin, D.J.; Chen, C.; Gordon, A.; Hannon, G.J. Probing the
initiation and effector phases of the somatic piRNA pathway in Drosophila. Genes Dev. 2010, 24, 2499–2504. [CrossRef]
Olivieri, D.; Sykora, M.M.; Sachidanandam, R.; Mechtler, K.; Brennecke, J. An in vivo RNAi assay identifies major genetic and
cellular requirements for primary piRNA biogenesis in Drosophila. EMBO J. 2010, 29, 3301–3317. [CrossRef]
Zamparini, A.L.; Davis, M.Y.; Malone, C.D.; Vieira, E.; Zavadil, J.; Sachidanandam, R.; Hannon, G.J.; Lehmann, R. Vreteno, a
gonad-specific protein, is essential for germline development and primary piRNA biogenesis in Drosophila. Development 2011,
138, 4039–4050. [CrossRef] [PubMed]
Handler, D.; Olivieri, D.; Novatchkova, M.; Gruber, F.S.; Meixner, K.; Mechtler, K.; Stark, A.; Sachidanandam, R.; Brennecke, J.
A systematic analysis of DrosophilaTUDOR domain-containing proteins identifies Vreteno and the Tdrd12 family as essential
primary piRNA pathway factors. EMBO J. 2011, 30, 3977–3993. [CrossRef] [PubMed]
Pane, A.; Wehr, K.; Schüpbach, T. zucchini and squash Encode Two Putative Nucleases Required for rasiRNA Production in the
Drosophila Germline. Dev. Cell 2007, 12, 851–862. [CrossRef]
Olivieri, D.; Senti, K.-A.; Subramanian, S.L.; Sachidanandam, R.; Brennecke, J. The Cochaperone Shutdown Defines a Group of
Biogenesis Factors Essential for All piRNA Populations in Drosophila. Mol. Cell 2012, 47, 954–969. [CrossRef] [PubMed]
Preall, J.B.; Czech, B.; Guzzardo, P.M.; Muerdter, F.; Hannon, G.J. shutdown is a component of the Drosophila piRNA biogenesis
machinery. RNA 2012, 18, 1446–1457. [CrossRef]
Horwich, M.D.; Li, C.; Matranga, C.; Vagin, V.; Farley, G.; Wang, P.; Zamore, P.D. The Drosophila RNA Methyltransferase,
DmHen1, Modifies Germline piRNAs and Single-Stranded siRNAs in RISC. Curr. Biol. 2007, 17, 1265–1272. [CrossRef] [PubMed]
Malone, C.D.; Brennecke, J.; Dus, M.; Stark, A.; McCombie, W.R.; Sachidanandam, R.; Hannon, G.J. Specialized piRNA Pathways
Act in Germline and Somatic Tissues of the Drosophila Ovary. Cell 2009, 137, 522–535. [CrossRef] [PubMed]
Gunawardane, L.S.; Saito, K.; Nishida, K.M.; Miyoshi, K.; Kawamura, Y.; Nagami, T.; Siomi, H.; Siomi, M.C. A Slicer-Mediated
Mechanism for Repeat-Associated siRNA 5’ End Formation in Drosophila. Science 2007, 315, 1587–1590. [CrossRef]
Lim, A.K.; Kai, T. Unique germ-line organelle, nuage, functions to repress selfish genetic elements in Drosophila melanogaster.
Proc. Natl. Acad. Sci. USA 2007, 104, 6714–6719. [CrossRef]
Patil, V.S.; Kai, T. Repression of Retroelements in Drosophila Germline via piRNA Pathway by the Tudor Domain Protein Tejas.
Curr. Biol. 2010, 20, 724–730. [CrossRef] [PubMed]
Cook, H.A.; Koppetsch, B.S.; Wu, J.; Theurkauf, W.E. The Drosophila SDE3 Homolog armitage Is Required for oskar mRNA
Silencing and Embryonic Axis Specification. Cell 2004, 116, 817–829. [CrossRef]
Han, B.W.; Zamore, P.D. PiRNAs. Curr. Biol. 2014, 24, R730–R733. [CrossRef]
Calcagno, D.Q.; Mota, E.R.D.S.; Moreira, F.; De Sousa, S.B.M.; Burbano, R.R.; Assumpção, P.P.; Patel, V.; Preedy, V. Role of PIWIInteracting RNA (piRNA) as Epigenetic Regulation. In Handbook of Nutrition, Diet, and Epigenetics; Springer: Berlin/Heidelberg,
Germany, 2017; pp. 1–23.
Gainetdinov, I.; Colpan, C.; Arif, A.; Cecchini, K.; Zamore, P.D. A Single Mechanism of Biogenesis, Initiated and Directed by PIWI
Proteins, Explains piRNA Production in Most Animals. Mol. Cell 2018, 71, 775–790. [CrossRef] [PubMed]
Ayarpadikannan, S.; Kim, H.-S. The Impact of Transposable Elements in Genome Evolution and Genetic Instability and Their
Implications in Various Diseases. Genom. Inform. 2014, 12, 98–104. [CrossRef] [PubMed]
Ng, K.W.; Anderson, C.S.; Marshall, E.A.; Minatel, B.C.; Enfield, K.S.S.; Saprunoff, H.L.; Lam, W.L.; Martinez, V.D. Piwi-interacting
RNAs in cancer: Emerging functions and clinical utility. Mol. Cancer 2016, 15, 1–13. [CrossRef] [PubMed]
Chen, Y.; Pane, A.; Schüpbach, T. Cutoff and aubergine Mutations Result in Retrotransposon Upregulation and Checkpoint
Activation in Drosophila. Curr. Biol. 2007, 17, 637–642. [CrossRef]
Sarot, E.; Payen-Groschêne, G.; Bucheton, A.; Pélisson, A. Evidence for a piwi-Dependent RNA Silencing of the gypsy Endogenous
Retrovirus by the Drosophila melanogaster flamenco Gene. Genetics 2004, 166, 1313–1321. [CrossRef]
Girard, A.; Hannon, G.J. Conserved themes in small-RNA-mediated transposon control. Trends Cell Biol. 2008, 18, 136–148.
[CrossRef]

Int. J. Mol. Sci. 2021, 22, 2373

73.
74.

75.
76.

77.

78.
79.
80.
81.
82.
83.
84.
85.
86.
87.

88.
89.

90.

91.
92.
93.
94.
95.
96.
97.
98.

19 of 22

Biryukova, I.; Ye, T. Endogenous siRNAs and piRNAs derived from transposable elements and genes in the malaria vector
mosquito Anopheles gambiae. BMC Genom. 2015, 16, 278. [CrossRef] [PubMed]
Vagin, V.V.; Klenov, M.S.; Kalmykova, A.; Stolyarenko, A.D.; Kotelnikov, R.N.; Gvozdev, V.A. The RNA interference proteins and
vasa locus are involved in the silencing of retrotransposons in the female germline of Drosophila melanogaster. RNA Biol. 2004, 1,
53–57. [CrossRef]
Savitsky, M.; Kwon, D.; Georgiev, P.; Kalmykova, A.; Gvozdev, V. Telomere elongation is under the control of the RNAi-based
mechanism in the Drosophila germline. Genes Dev. 2006, 20, 345–354. [CrossRef] [PubMed]
Pélisson, A.; Sarot, E.; Payen-Groscheêne, G.; Bucheton, A. A Novel Repeat-Associated Small Interfering RNA-Mediated Silencing
Pathway Downregulates Complementary Sense Gypsy Transcripts in Somatic Cells of the Drosophila Ovary. J. Virol. 2006, 81,
1951–1960. [CrossRef] [PubMed]
Shpiz, S.; Kwon, D.; Uneva, A.; Kim, M.; Klenov, M.; Rozovsky, Y.; Georgiev, P.; Savitsky, M.; Kalmykova, A. Characterization of
Drosophila Telomeric Retroelement TAHRE: Transcription, Transpositions, and RNAi-based Regulation of Expression. Mol. Biol.
Evol. 2007, 24, 2535–2545. [CrossRef]
Li, C.; Vagin, V.V.; Lee, S.; Xu, J.; Ma, S.; Xi, H.; Seitz, H.; Horwich, M.D.; Syrzycka, M.; Honda, B.M.; et al. Collapse of Germline
piRNAs in the Absence of Argonaute3 Reveals Somatic piRNAs in Flies. Cell 2009, 137, 509–521. [CrossRef]
Carmell, M.A.; Girard, A.; Van De Kant, H.J.G.; Bourc’His, D.; Bestor, T.H.; De Rooij, D.G.; Hannon, G.J. MIWI2 Is Essential for
Spermatogenesis and Repression of Transposons in the Mouse Male Germline. Dev. Cell 2007, 12, 503–514. [CrossRef]
Huang, X.A.; Yin, H.; Sweeney, S.; Raha, D.; Snyder, M.; Lin, H. A Major Epigenetic Programming Mechanism Guided by piRNAs.
Dev. Cell 2013, 24, 502–516. [CrossRef]
Yin, H.; Lin, H. An epigenetic activation role of Piwi and a Piwi-associated piRNA in Drosophila melanogaster. Nat. Cell Biol.
2007, 450, 304–308. [CrossRef]
Watanabe, T.; Cui, X.; Yuan, Z.; Qi, H.; Lin, H. MIWI2 targets RNAs transcribed from piRNA-dependent regions to drive DNA
methylation in mouse prospermatogonia. EMBO J. 2018, 37, e95329. [CrossRef] [PubMed]
Pal-Bhadra, M.; Leibovtch, B.A.; Gandhi, S.G.; Rao, M.; Bhadra, U.; Birchler, J.A.; Elgin, S.C.R. Heterochromatic Silencing and
HP1 Localization in Drosophila are Dependent on the RNAi Machinery. Science 2004, 303, 669–672. [CrossRef] [PubMed]
Pal-Bhadra, M.; Bhadra, U.; Birchler, J.A. RNAi Related Mechanisms Affect Both Transcriptional and Posttranscriptional Transgene
Silencing in Drosophila. Mol. Cell 2002, 9, 315–327. [CrossRef]
Gomes, A.Q.; Nolasco, S.; Soares, H. Non-Coding RNAs: Multi-Tasking Molecules in the Cell. Int. J. Mol. Sci. 2013, 14,
16010–16039. [CrossRef]
Rajasethupathy, P.; Antonov, I.; Sheridan, R.; Frey, S.; Sander, C.; Tuschl, T.; Kandel, E.R. A Role for Neuronal piRNAs in the
Epigenetic Control of Memory-Related Synaptic Plasticity. Cell 2012, 149, 693–707. [CrossRef]
Kuramochi-Miyagawa, S.; Watanabe, T.; Gotoh, K.; Totoki, Y.; Toyoda, A.; Ikawa, M.; Asada, N.; Kojima, K.; Yamaguchi, Y.;
Ijiri, T.W.; et al. DNA methylation of retrotransposon genes is regulated by Piwi family members MILI and MIWI2 in murine
fetal testes. Genes Dev. 2008, 22, 908–917. [CrossRef]
Fu, A.; Jacobs, D.I.; Zhu, Y. Epigenome-wide analysis of piRNAs in gene-specific DNA methylation. RNA Biol. 2014, 11, 1301–1312.
[CrossRef]
Zoch, A.; Auchynnikava, T.; Berrens, R.V.; Kabayama, Y.; Schopp, T.; Heep, M.; Vasiliauskaite, L.; Pere-Rico, Y.A.; Cook, A.G.;
Shkumatava, A.; et al. SPOCD1 is an essential executor of piRNA-directed de novo DNA methylation. Nature 2020, 584, 635–639.
[CrossRef]
Schöpp, T.; Zoch, A.; Berrens, R.V.; Auchynnikava, T.; Kabayama, Y.; Vasiliauskaitė, L.; Rappsilber, J.; Allshire, R.C.; O’Carroll, D.
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